questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Oxidoreductases
Alcohol oxidoreductases
NAD (+) and NADP (+) dependent Alcohol oxidoreductases
3-Hydroxyacyl-CoA dehydrogenases
Hydroxymethylglutaryl-CoA reductases
Hydroxymethylglutaryl-CoA reductases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Dyslipidémie
Cholestérol
Enzymes hépatiques
Échographie
Fonction hépatique
Tests de laboratoire
Tests génétiques
Mutations
Dyslipidémie
Cholestérol
Maladies cardiovasculaires
Dyslipidémie
Tests enzymatiques
Hydroxyméthylglutaryl-CoA
Dyslipidémie
Symptômes
5
Hypercholestérolémie
Douleurs thoraciques
Fatigue
Maladies cardiovasculaires
Cholestérol
Dépôts lipidiques
Xanthomes
Lipides
Dyslipidémie
Asymptomatique
Cholestérol
Dyslipidémie
Troubles de la vision
Douleurs abdominales
Dyslipidémie
Prévention
5
Prévention
Alimentation équilibrée
Exercice physique
Tabagisme
Dyslipidémie
Maladies cardiovasculaires
Alcool
Cholestérol
Dyslipidémie
Contrôles médicaux
Cholestérol
Dyslipidémie
Alimentation
Fibres
Santé
Traitements
5
Statines
Cholestérol
Dyslipidémie
Changements de mode de vie
Alimentation
Exercice physique
Statines
Hydroxyméthylglutaryl-CoA
Cholestérol
Suivi médical
Cholestérol
Dyslipidémie
Effets secondaires
Douleurs musculaires
Troubles digestifs
Complications
5
Maladies cardiaques
AVC
Athérosclérose
Athérosclérose
Cholestérol
Dyslipidémie
Maladies hépatiques
Stéatose
Dyslipidémie
Risques cardiovasculaires
Crises cardiaques
AVC
Réversibilité
Traitement
Changements de mode de vie
Facteurs de risque
5
Obésité
Tabagisme
Inactivité physique
Hérédité
Antécédents familiaux
Dyslipidémie
Stress
Cholestérol
Dyslipidémie
Âge
Dyslipidémie
Facteurs de risque
Diabète
Maladies chroniques
Dyslipidémie
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases : Questions médicales les plus fréquentes",
"headline": "Hydroxymethylglutaryl-CoA reductases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hydroxymethylglutaryl-CoA reductases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-29",
"dateModified": "2025-03-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "3-Hydroxyacyl-CoA dehydrogenases",
"url": "https://questionsmedicales.fr/mesh/D015094",
"about": {
"@type": "MedicalCondition",
"name": "3-Hydroxyacyl-CoA dehydrogenases",
"code": {
"@type": "MedicalCode",
"code": "D015094",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.047.820.150"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"alternateName": "Hydroxymethylglutaryl-CoA Reductases, NAD-Dependent",
"url": "https://questionsmedicales.fr/mesh/D025781",
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"code": {
"@type": "MedicalCode",
"code": "D025781",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.047.820.150.415.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"alternateName": "Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent",
"url": "https://questionsmedicales.fr/mesh/D025782",
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"code": {
"@type": "MedicalCode",
"code": "D025782",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.047.820.150.415.750"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases",
"alternateName": "Hydroxymethylglutaryl CoA Reductases",
"code": {
"@type": "MedicalCode",
"code": "D006903",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Russell A DeBose-Boyd",
"url": "https://questionsmedicales.fr/author/Russell%20A%20DeBose-Boyd",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA."
}
},
{
"@type": "Person",
"name": "Youngah Jo",
"url": "https://questionsmedicales.fr/author/Youngah%20Jo",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA."
}
},
{
"@type": "Person",
"name": "George Davey Smith",
"url": "https://questionsmedicales.fr/author/George%20Davey%20Smith",
"affiliation": {
"@type": "Organization",
"name": "Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom."
}
},
{
"@type": "Person",
"name": "Hiromasa Yoshioka",
"url": "https://questionsmedicales.fr/author/Hiromasa%20Yoshioka",
"affiliation": {
"@type": "Organization",
"name": "Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113 0032, Japan."
}
},
{
"@type": "Person",
"name": "Kenji Ohgane",
"url": "https://questionsmedicales.fr/author/Kenji%20Ohgane",
"affiliation": {
"@type": "Organization",
"name": "Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113 0032, Japan. Electronic address: ohgane@rs.tus.ac.jp."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Within-subject variation of C-reactive protein and high-sensitivity C-reactive protein: A systematic review and meta-analysis.",
"datePublished": "2024-11-01",
"url": "https://questionsmedicales.fr/article/39485740",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0304961"
}
},
{
"@type": "ScholarlyArticle",
"name": "Role of C-Reactive Protein in Diabetic Inflammation.",
"datePublished": "2022-05-17",
"url": "https://questionsmedicales.fr/article/35620114",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/3706508"
}
},
{
"@type": "ScholarlyArticle",
"name": "C-reactive protein, immunothrombosis and venous thromboembolism.",
"datePublished": "2022-09-13",
"url": "https://questionsmedicales.fr/article/36177015",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2022.1002652"
}
},
{
"@type": "ScholarlyArticle",
"name": "C-Reactive Protein-to-Prealbumin and C-Reactive Protein-to-Albumin Ratios as Nutritional and Prognostic Markers in Hospitalized Patients-An Observational Study.",
"datePublished": "2024-08-08",
"url": "https://questionsmedicales.fr/article/39203747",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/nu16162610"
}
},
{
"@type": "ScholarlyArticle",
"name": "C-reactive protein/albumin and C-reactive protein/fibrinogen ratios for the diagnosis of periprosthetic joint infection in revision total joint arthroplasty.",
"datePublished": "2023-01-07",
"url": "https://questionsmedicales.fr/article/36623413",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.intimp.2023.109682"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D010088"
},
{
"@type": "ListItem",
"position": 5,
"name": "Alcohol oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D000429"
},
{
"@type": "ListItem",
"position": 6,
"name": "NAD (+) and NADP (+) dependent Alcohol oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D064430"
},
{
"@type": "ListItem",
"position": 7,
"name": "3-Hydroxyacyl-CoA dehydrogenases",
"item": "https://questionsmedicales.fr/mesh/D015094"
},
{
"@type": "ListItem",
"position": 8,
"name": "Hydroxymethylglutaryl-CoA reductases",
"item": "https://questionsmedicales.fr/mesh/D006903"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hydroxymethylglutaryl-CoA reductases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hydroxymethylglutaryl-CoA reductases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-30",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hydroxymethylglutaryl-CoA reductases",
"description": "Comment diagnostiquer une dysfonction des réductases ?\nQuels examens sont recommandés pour évaluer les réductases ?\nLes tests génétiques sont-ils utiles ?\nQuels symptômes indiquent un problème avec les réductases ?\nComment évaluer l'activité des réductases ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=C-Reactive+Protein#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quels sont les symptômes d'une hypercholestérolémie ?\nComment se manifeste une maladie liée aux réductases ?\nY a-t-il des signes cutanés associés ?\nLes symptômes sont-ils toujours présents ?\nQuels autres symptômes peuvent survenir ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=C-Reactive+Protein#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hydroxymethylglutaryl-CoA reductases",
"description": "Comment prévenir les problèmes liés aux réductases ?\nLe tabagisme influence-t-il les réductases ?\nL'alcool a-t-il un impact sur le cholestérol ?\nLes contrôles médicaux réguliers sont-ils importants ?\nQuels aliments privilégier pour la santé des réductases ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=C-Reactive+Protein#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quels médicaments sont utilisés pour traiter les dysfonctionnements ?\nY a-t-il des traitements non médicamenteux ?\nComment les statines agissent-elles ?\nLes traitements sont-ils efficaces à long terme ?\nQuels effets secondaires peuvent survenir ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=C-Reactive+Protein#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quelles complications peuvent survenir avec une dyslipidémie ?\nComment l'athérosclérose est-elle liée aux réductases ?\nLes maladies hépatiques sont-elles une complication ?\nQuels risques cardiovasculaires sont associés ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=C-Reactive+Protein#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quels sont les principaux facteurs de risque ?\nL'hérédité joue-t-elle un rôle ?\nLe stress influence-t-il les niveaux de cholestérol ?\nL'âge est-il un facteur de risque ?\nLes maladies chroniques influencent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=C-Reactive+Protein#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des réductases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux de cholestérol et des enzymes hépatiques sont effectués."
}
},
{
"@type": "Question",
"name": "Quels examens sont recommandés pour évaluer les réductases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une échographie abdominale et des tests de fonction hépatique peuvent être recommandés."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier des mutations génétiques affectant les réductases."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème avec les réductases ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de cholestérol et des maladies cardiovasculaires peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'activité des réductases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques spécifiques peuvent mesurer l'activité des hydroxyméthylglutaryl-CoA réductases."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une hypercholestérolémie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs thoraciques, fatigue et problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Comment se manifeste une maladie liée aux réductases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se manifester par des dépôts de cholestérol dans les artères et des douleurs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des xanthomes peuvent apparaître, indiquant une accumulation de lipides."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains patients peuvent être asymptomatiques malgré des niveaux élevés de cholestérol."
}
},
{
"@type": "Question",
"name": "Quels autres symptômes peuvent survenir ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de la vision et des douleurs abdominales peuvent également se manifester."
}
},
{
"@type": "Question",
"name": "Comment prévenir les problèmes liés aux réductases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et l'exercice régulier aident à maintenir un bon cholestérol."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il les réductases ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente le risque de dyslipidémie et de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "L'alcool a-t-il un impact sur le cholestérol ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une consommation excessive d'alcool peut aggraver les niveaux de cholestérol."
}
},
{
"@type": "Question",
"name": "Les contrôles médicaux réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent de détecter précocement les anomalies du cholestérol."
}
},
{
"@type": "Question",
"name": "Quels aliments privilégier pour la santé des réductases ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les aliments riches en fibres, comme les fruits et légumes, sont bénéfiques."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour traiter les dysfonctionnements ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les statines sont couramment prescrites pour réduire le cholestérol sanguin."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements non médicamenteux ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des changements de mode de vie comme l'alimentation et l'exercice sont recommandés."
}
},
{
"@type": "Question",
"name": "Comment les statines agissent-elles ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles inhibent l'hydroxyméthylglutaryl-CoA réductase, réduisant ainsi la production de cholestérol."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à long terme ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avec un suivi régulier, les traitements peuvent maintenir des niveaux de cholestérol sains."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs musculaires et des troubles digestifs sont des effets secondaires possibles."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une dyslipidémie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent les maladies cardiaques, les AVC et l'athérosclérose."
}
},
{
"@type": "Question",
"name": "Comment l'athérosclérose est-elle liée aux réductases ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une production excessive de cholestérol due à des réductases dysfonctionnelles peut provoquer l'athérosclérose."
}
},
{
"@type": "Question",
"name": "Les maladies hépatiques sont-elles une complication ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une accumulation de lipides peut entraîner des maladies hépatiques comme la stéatose."
}
},
{
"@type": "Question",
"name": "Quels risques cardiovasculaires sont associés ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux élevés de cholestérol augmentent le risque de crises cardiaques et d'AVC."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié et des changements de mode de vie."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'obésité, le tabagisme, l'inactivité physique et une mauvaise alimentation."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de dyslipidémie augmentent le risque de problèmes liés aux réductases."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il les niveaux de cholestérol ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer à des niveaux de cholestérol élevés."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de dyslipidémie augmente avec l'âge, surtout après 45 ans."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques influencent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme le diabète augmentent le risque de dyslipidémie et de complications."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 26/03/2025
Contenu vérifié selon les dernières recommandations médicales
7 publications dans cette catégorie
Affiliations :
Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA.
4 publications dans cette catégorie
Affiliations :
Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
3 publications dans cette catégorie
Affiliations :
Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.
Population Health Science, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
3 publications dans cette catégorie
Affiliations :
Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113 0032, Japan.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
3 publications dans cette catégorie
Affiliations :
Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113 0032, Japan. Electronic address: ohgane@rs.tus.ac.jp.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Louisiana State University; Baton Rouge, LA 70803, USA. Electronic address: mtkalc1@lsu.edu.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Louisiana State University; Baton Rouge, LA 70803, USA. Electronic address: gwaldro@lsu.edu.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Kunming Institute of Botany Chinese Academy of Sciences, State Key Laboratory of Phytochemistry and Plant Resources in West China, CHINA.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
National Institute for Health and Welfare, Helsinki, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Medical Research Council Population Health Research Unit, University of Oxford, Oxford, United Kingdom.
Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
National Institute for Health Research, Oxford Biomedical Research Centre, Oxford University Hospital, Oxford, United Kingdom.
Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
Homerton College, University of Cambridge, Cambridge, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Institute of Cardiovascular Science, University College London, London, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Institute of Cardiovascular Science, University College London, London, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Physiology, University of Tampere and Tampere University Hospital, Tampere, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Chemistry, Fimlab Laboratories, Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Health Technologies, University of Tampere, Tampere, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine, University of Turku, Turku, Finland.
Division of Medicine, Turku University Hospital, Turku, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
C-reactive protein (CRP) and high-sensitivity C-reactive protein (hsCRP) are measures of inflammation used in diagnosis, to guide treatment decisions, and in disease prediction. Variability in measure...
A systematic review and meta-analysis was performed to estimate longitudinal within-subject variability of CRP and hsCRP over any time period. Follow-up studies of any design in adults or children, wi...
Of 2675 studies identified, 60 met the inclusion criteria: 34 reported CRP and 26 reported hsCRP. For CRP, median CV was 0.41 (range 0.11 to 0.89), and the pooled estimate of ICC was 0.55 (95% CI 0.35...
Assessment of variability was not the main aim of many of the included papers, and it is possible that some relevant papers have been missed. Many of the papers included had low numbers of participant...
Estimated within-subject variability is high for both CRP and hsCRP, but estimates are based on small numbers of participants and measurements. There is a need for better estimates of within-subject v...
Even though type 2 diabetes mellitus (T2DM) represents a worldwide chronic health issue that affects about 462 million people, specific underlying determinants of insulin resistance (IR) and impaired ...
C-reactive protein (CRP) is a member of the highly conserved pentraxin superfamily of proteins and is often used in clinical practice as a marker of infection and inflammation. There is now increasing...
This study aimed to evaluate the role of the C-reactive protein-to-prealbumin (CP) ratio and the C-reactive protein-to-albumin (CA) ratio as nutritional and prognostic markers. A retrospective study w...
Testing for systemic inflammation markers is considered a simpler method for diagnosing periprosthetic joint infection (PJI). Changes in the C-reactive protein/albumin ratio (CRP/Alb ratio) and C-reac...
We retrospectively evaluated 445 patients who underwent total hip and knee revision arthroplasties between January 2010 and February 2021. Of these, 129 patients were also independently evaluated for ...
The AUC values of the CRP/Alb and CRP/Fib ratios were 0.880 and 0.872, respectively, suggesting similar diagnostic potentials for PJI. The CRP/Alb and CRP/Fib ratios were better than the erythrocyte s...
Both the CRP/Alb and CRP/Fib ratios were significantly higher in patients with PJI than in those with aseptic failure and showed better sensitivity and specificity for diagnosing PJI than classical in...
The quantification of protein biomarkers in blood at picomolar-level sensitivity requires labour-intensive incubation and washing steps. Sensing proteins in sweat, which would allow for point-of-care ...
Human C-reactive protein (CRP) binds to lipophosphoglycan (LPG), a virulence factor of...
C-reactive protein (CRP) is well-recognized as a sensitive biomarker of inflammation. Association of elevations in plasma/serum CRP level with disease state has received considerable attention, even t...
In a retrospective study, we analyzed the prevalence of elevated C‑reactive protein (CRP) serum levels in 148 patients with chronic myelomonocytic leukemia (CMML), their potential prognostic impact, a...
Hypertension has become an important health risk factor in the twenty-first century, especially for the elderly. Studies have confirmed that inflammation is involved in the development of hypertension...
Serum CRP levels were measured in 196 hospitalized patients, and the CRP level was used as a criterion to divide them into the group with elevated CRP (> 10 mmol/L, n = 120) and the group with normal ...
The prevalence of hypertension, coronary artery disease and joint reactive inflammation was significantly higher in the group with elevated CRP. There was also a significant association between the us...
Elevated CRP, BMI, and diabetes are positively associated with hypertension in the elderly, and early screening for CRP and initiation of treatment may help prevent further inflammatory responses in h...